Anzeige
Mehr »
Mittwoch, 10.09.2025 - Börsentäglich über 12.000 News
Warum diese Aktie jetzt das perfekte Chance-Risiko-Profil für Investoren bietet
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PBYQ | ISIN: US29350E1047 | Ticker-Symbol: 2Q5
Frankfurt
09.09.25 | 08:05
0,120 Euro
-2,60 % -0,003
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
LUNAI BIOWORKS INC Chart 1 Jahr
5-Tage-Chart
LUNAI BIOWORKS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,1790,18109.09.

Aktuelle News zur LUNAI BIOWORKS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
LUNAI BIOWORKS Aktie jetzt für 0€ handeln
DiLunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery211Proprietary safety intelligence creates dual value: faster therapeutic development and biodefense. LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 9, 2025 / Lunai Bioworks Inc. (NASDAQ:RENB),...
► Artikel lesen
MoLunai Bioworks Strengthens European Strategy Through Restructuring157Company remains committed to Europe with a streamlined, growth-focused approach. LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 8, 2025 / Lunai Bioworks Inc. (Nasdaq:RENB), an AI-powered drug...
► Artikel lesen
DoLunai Bioworks partners with defense firm to develop chemical weapons countermeasures1
DoLunai Bioworks Inc. Retains American Defense International207Collaboration aims to apply Lunai Bioworks Inc. biomedical AI platform to accelerate countermeasure development for chemical agents like sarin and other biothreats LOS ANGELES, CALIFORNIA / ACCESS Newswire...
► Artikel lesen
27.08.Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnostics336LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 27, 2025 / Renovaro Inc. (NASDAQ:RENB) today announced that it will change its corporate name to Lunai Bioworks, Inc. to better reflect its strategic...
► Artikel lesen
26.08.Renovaro Inc. firmiert in Lunai Bioworks Inc. um, Tickersymbol an der NASDAQ bleibt bestehen5
26.08.RENOVARO INC. - 8-K, Current Report2
08.08.Renovaro Inc. Mentioned in RealClearDefense Article on AI and Biodefense Risks345LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 8, 2025 / Renovaro Inc. (NASDAQ:RENB) was referenced in a recent RealClearDefense article titled "AI Can Be Used to Develop Biological and Chemical...
► Artikel lesen
06.08.RENOVARO INC. - 8-K, Current Report3
28.07.Renovaro Inc.: Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector300Strategic IP expansion protects federated learning technology driving pharma partnerships, biosecurity initiatives, and precision medicine growth LOS ANGELES, CALIFORNIA / ACCESS Newswire / July 28...
► Artikel lesen
27.07.Renovaro: Aufsichtsratsvorsitzender Maurice van Tilburg tritt im August 2025 zurück5
25.07.RENOVARO INC. - 8-K, Current Report1
17.07.Renovaro Biosciences: Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy278Landmark preclinical data validate Renovaro's platform representing a step forward in the fight against pancreatic and solid tumors LOS ANGELES, CALIFORNIA / ACCESS Newswire / July 17, 2025 / Renovaro...
► Artikel lesen
14.07.RENOVARO INC. - 8-K, Current Report3
09.07.Renovaro Inc.: Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven Initiatives308LOS ANGELES, CA / ACCESS Newswire / July 9, 2025 / Renovaro Inc. (NASDAQ:RENB), an AI-driven precision medicine company, today announced that senior debt holders have agreed to convert an aggregate...
► Artikel lesen
30.06.Renovaro Inc.: Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs305LOS ANGELES, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Renovaro Inc.'s (NASDAQ:RENB) wholly owned subsidiary BioSymetrics has unveiled a proprietary AI-based zebrafish screening platform designed...
► Artikel lesen
05.06.RENOVARO INC. - 8-K, Current Report5
03.06.Renovaro subsidiary secures patent for drug discovery AI9
03.06.Renovaro Inc: Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform3
27.05.Predictive Oncology to defend against Renovaro's claims in court9
Weiter >>
56 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,10